The Affordable Care Act has been touted as a means to control costs and improve quality of care. One initiative in that effort is to steer patients away from visiting the emergency department (ED). That undertaking may prove to be challenging.
The Affordable Care Act has been touted as a means to control costs and improve quality of care. One initiative in that effort is to steer patients away from visiting the emergency department (ED). That undertaking may prove to be challenging, especially in light of a recent report which found that people in Oregon who gained coverage through Medicaid used the ED 40% more than those who were uninsured. These findings disprove the myth that suggests it is only the uninsured who end up getting treated in hospital EDs.
“I would view it as part of a broader set of evidence that covering people with health insurance doesn’t save money,” says Jonathan Gruber, a health economist at the Massachusetts Institute of Technology. “That was sometimes a misleading motivator for the Affordable Care Act. The law isn’t designed to save money. It’s designed to improve health, and that’s going to cost money.”
Additionally, some hospitals are building EDs specifically tailored to the aging population. While promising for elderly patients, who are more likely to have complex or chronic conditions and be readmitted, they may not be cost-effective. Senior-specific EDs costs can range from $150,000 to $3.2 million to operate, depending on the number of patients a hospital treats.
“Is this money being well spent? There are some instances where this might improve readmission rates. (But) true robust data is not yet available for outcomes for senior-specific EDs,” said Robert Maliff, director of ECRI’s Applied Solutions Group.
According to the ECRI Institute’s 2014 Top 10 Hospital C-Suite Watch List, there are 10 clinical developments, tools, and technologies that healthcare executives should be aware of, including EDs tailored to elder care. The group notes that the suggestions they offer are not a list of “must-haves,” but rather a list of “must-think-carefully-about” technologies and health-system issues. They suggest the following should be on hospital radars:
Around the Web
Growth of Senior-Specific EDs Holds Quality Promise but Raises Cost Issues [Modern Healthcare]
Study: Expanding Medicaid Doesn’t Reduce ER Trips. It Increases Them. [The Washington Post]
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More